November 25, 2019 / 7:20 AM / 16 days ago

BRIEF-Novartis CEO Sees Solid Payer Acceptance of Cholesterol Drug

Nov 25 (Reuters) - Novartis:

* CEO SAYS CONFIDENT CAN GENERATE ATTRACTIVE RETURN ON TAKEOVER OF THE MEDICINES CO

* CEO SAYS CONFIDENT OF OFFSETTING GENERIC EROSION

* CEO SAYS AIMS TO PRICE INCLISIRAN WITHIN COST-EFFECTIVENESS RANGE FOR CHOLESTEROL DRUGS, DOES NOT DISCLOSE SPECIFICS

* CEO SAYS NOT ENDEAVORING TO TARGET PATIENTS TO SWITCH FROM CURRENT PCSK9 THERAPIES

* CEO SAYS BELIEVES THERE WILL BE SOLID PAYER ACCEPTANCE OF INCLISIRAN, UPTAKE TO BUILD OVER TIME UNTIL 2037 AFTER PATENTS EXPIRE

* CEO SAYS SEES FEW YEARS OF SLOW RAMP UP OF INCLISIRAN, FOLLOWED BY SIGNIFICANT UPTAKE Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below